Keybanc Maintains Overweight on La-Z-Boy, Lowers Price Target to $40
Keybanc analyst Bradley B. Thomas maintains La-Z-Boy (NYSE:LZB) with a Overweight and lowers the price target from $46 to $40.
Read original at benzingaStocks · News reference
La-Z-Boy Q1 Adj. EPS $0.43 Misses $0.49 Estimate, Sales $475.689M Miss $501.340M Estimate
La-Z-Boy (NYSE:LZB) reported quarterly earnings of $0.43 per share which missed the analyst consensus estimate of $0.49 by 12.24 percent. This is a 8.51 percent decrease over earnings of $0.47 per share from the same
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 18, 2026, 8:16 PM
- Checked
- Aug 18, 2026, 8:16 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
La-Z-Boy Q1 2027 Earnings Call: Complete Transcript
La-Z-Boy (NYSE:LZB) released first-quarter financial results and hosted an earnings call on Wednesday. Read the complete transcript below. This transcript is brought to you by Benzinga APIs. For real-time access to our
Read original at benzingaLa-Z-Boy shares are trading lower after the company reported worse-than-expected Q1 financial results and issued Q2 sales guidance below estimates.
Read original at benzingaMarket-Moving News for August 19th
TNON: 110% | Tenon Medical shares are trading higher after the company received a notice of allowance for a U.S. Patent Titled "Systems, Apparatus and Methods for Stabilizing Sacroiliac Joints" LZB: -18% |
Read original at benzinga